basilea

Welcome

Program

Welcome

Basilea's story – Our vision and mission

Strategic alignment – Our business model for financial growth

Innovative compounds in the anti-infectives area – Our exciting portfolio

Coffee break & Networking

Program

Treating infectious diseases

Progress, current limitations and future needs

— **Prof. Oliver A. Cornely** – Invasive fungal infections

— **Prof. Thomas L. Holland** – *Staphylococcus aureus* bacteremia

Round table and Q&A

Key takeaways & wrap-up

Networking & Apéro

basilea

David Veitch

Chief Executive Officer


basilea


basilea
BSLN

basilea

What we do


basilea
Serious bacterial
& fungal infections

Successful track record of sales performance

basilea

$ 500 million – $ 1 billion revenues in the market

Creating a broad portfolio

basilea

Antibacterials

- Zevtera
- Tonabacase
- LptA inhibitor

Antifungals

- Cresemba
- Fosmanogepix
- BAL2062

Our capabilities

basilea

Partnerships

basilea

Industry

Non-profit organizations

BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY
BARDA

CARB-X

Unique & successful business model


basilea
Clear vision
and mission


basilea
Leader in
anti-infectives


basilea
Making a difference
to patients


basilea
7.7
million
people
die every year due to bacterial infections


basilea
6.5
million
people
are affected by invasive fungal infections every year
and 3.8 million people die, with 2.5 million deaths directly attributable to that fungal disease


basilea
Global systemic antifungals market 2023:
4.4
billion
USD

basilea

Global systemic hospital antibiotics market 2023:

17.8 billion USD

Challenges

Creating anti-infective opportunities

basilea

How?

Our recipe for success

basilea

6

elements for success

1.

Identify opportunities in anti-infectives

Our recipe for success

How we create anti-infective opportunities

Identify opportunities in anti-infectives

- Focus on areas with meaningful market opportunity today
- Focus on high priority diseases/pathogens

2.
Extend portfolio with external assets

Our recipe for success

How we create anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
  - Focus on areas with meaningful market opportunity today
  - Focus on high priority diseases/pathogens

Extend portfolio with external assets

- Affordable assets to in-license and acquire

3.

Define right development stage to create value

Our recipe for success

How we create anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
  - Focus on areas with meaningful market opportunity today
  - Focus on high priority diseases/pathogens
- ✓ **Extend portfolio with external assets**
  - Affordable assets to in-license and acquire

Define right development stage to create value

4.

Have sufficient cash to finance R&D

Our recipe for success

How we create anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
  - Focus on areas with meaningful market opportunity today
  - Focus on high priority diseases/pathogens
- ✓ **Extend portfolio with external assets**
  - Affordable assets to in-license and acquire
- ✓ **Define right development stage to create value**

Have sufficient cash to finance R&D

5.

Gain access to non-dilutive funding

Our recipe for success

How we create anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
  - Focus on areas with meaningful market opportunity today
  - Focus on high priority diseases/pathogens
- ✓ **Extend portfolio with external assets**
  - Affordable assets to in-license and acquire
- ✓ **Define right development stage to create value**
- ✓ **Have sufficient cash to finance R&D**

Gain access to non-dilutive funding

6.

Reduce the failure potential and maximize the success potential

Our recipe for success

How we create anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
  - — Focus on areas with meaningful market opportunity today
  - — Focus on high priority diseases/pathogens
- ✓ **Extend portfolio with external assets**
  - — Affordable assets to in-license and acquire
- ✓ **Define right development stage to create value**
- ✓ **Have sufficient cash to finance R&D**
- ✓ **Gain access to non-dilutive funding**

Reduce the failure potential and maximize the success potential

- — Commercialization by established partners
- — Select and prioritize assets through the scientific and commercial lens
- — Accept the development risk for the commercial gain

Great investment opportunity


basilea

basilea

Adesh Kaul

Chief Financial Officer

Our business model

basilea


CRESEMBA®
100 mg
hard capsules
Isavuconazole
Oral use.
Each hard capsule contains 100 mg isavuconazole
(as 186.3 mg isavuconazonium sulfate)
14 hard capsules
basilea
EU/1/15/1036/002
basilea
Zevtera® 500 mg
powder for concentrate for solution for infusion.
Ceftobiprole (as ceftobiprole medocaril sodium).
Each vial contains 500 mg of ceftobiprole,
equivalent to 666.6 mg of ceftobiprole medocaril sodium.
For intravenous use after reconstitution and dilution.
Read the package leaflet before use.
10 vials

Key success factors


basilea
Cover the entire pharmaceutical value chain
Lean & cost-effective

basilea

Leveraging partnerships

Making long-term decisions out of a position of financial strength

Our business model



Our business model

Preclinical | Phase 1 | Phase 2 | Phase 3 | Market

1.

Acquisition/ in-licensing of innovative anti-infective drugs

2.

Adding value through R&D

3.

Manufacturing and commercialization through partners

Our business model

Preclinical | Phase 1 | Phase 2 | Phase 3 | Market

1. Acquisition/ in-licensing of innovative anti-infective drugs

2. Adding value through R&D

3. Manufacturing and commercialization through partners

Our business model



Our business model



1.

Acquisition/ in-licensing of innovative anti-infective drugs

— In-licensing and acquisition of the most promising assets (research and early clinical development stages)

Our business model



2.

Adding value through R&D

- Focusing R&D investments on innovative assets with a clearly defined hypothesis on clinical differentiation and commercial positioning

BARDA — Biomedical Advanced Research and Development Authority

CARB-X

- Offsetting R&D expenses through **accessing non-dilutive push-incentives**

Our business model



3.

Manufacturing and commercialization through partners

- Manufacturing through contract manufacturing organizations (CMOs)
- Commercialization through partnerships with global, regional and local specialized pharmaceutical partners

basilea

License partners

Pfizer

astellas

AsahiKASEI

CR Gosun

Distribution partners

ADVANZ PHARMA

hikma.

Knight

UNIMEDIC PHARMA

AVIR PHARMA

LANCET

Financial participation in in-market product sales

Basilea: 30-40% of in-market product sales over the lifetime of a product





Basilea expected gross margin

Successful products



basilea

Cresemba® double-digit growth

USD 473 million in-market sales in the 12 months to December 2023



MAT: Moving annual total;
Source: IQVIA Analytics Link, December 2023

Cresemba® has significant growth potential

Recently launched in Japan and China, representing 25% of global potential

Global sales of best-in-class antifungals* (MAT Q4 2023)



MAT: Moving annual total; Source: IQVIA Analytics Link, December 2023

* Best-in-class antifungals: Cresemba (isavuconazole), posaconazole, voriconazole, AmBisome, anidulafungin, caspofungin, micafungin, rezafungin


basilea
basilea
Zevtera® 500 mg
powder for concentrate for solution for infusion.
Ceftobiprole (as ceftobiprole medocaril sodium).
Each vial contains 500 mg of ceftobiprole,
equivalent to 666.6 mg of ceftobiprole medocaril sodium.
For intravenous use after reconstitution and dilution.
Read the package leaflet before use.
10 vials

The hospital anti-MRSA antibiotic market

A USD 2.4 billion market* with the US being the most important region

Daptomycin sales by region (2015, before LOE)



MRSA: Methicillin-resistant *Staphylococcus aureus*; LOE: Loss of exclusivity; ROW: Rest Of World; MAT: Moving annual total; Source: IQVIA Analytics Link, December 2023

* Vancomycin, linezolid, teicoplanin, daptomycin, tigecycline, telavancin, ceftaroline, dalbavancin, ceftobiprole, oritavancin, and tedizolid (daptomycin and tigecycline are partial sales in the US in IQVIA data)


basilea
United States
Commercial
partner
Process completion around mid-year 2024

This commercial success
gives us the financial strength for

creating long-term value and growth

Cash flows from operating activities (in CHF million)



Debt reduction (in CHF million)



Figures as of the beginning of the fiscal year; rounding applied consistently

Strong 2024 guidance

20% increase in Cresemba and Zevtera related revenue and more than doubling of net profit

In CHF million	FY 2022	FY 2023 guidance	FY 2023	FY 2024 guidance
Cresemba and Zevtera related revenue	122.3	147 – 150	150.3	~180
of which royalty income	65.0	~76	78.9	~89
Total revenue	**147.8**	**154 – 157**	**157.6**	**~183**
Cost of products sold	24.6	~27	26.8	~33
Operating expenses	104.6	~115	111.6	~120
Operating profit	18.5	11 – 15	19.2	~30
Net profit	**12.1**	**2 – 6**	**10.5**	**~25**

Our recipe for success

How we create anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
  - Focus on areas with meaningful market opportunity today
  - Focus on high priority diseases/pathogens
- ✓ **Extend portfolio with external assets**
  - Affordable assets to in-license and acquire
- ✓ **Define right development stage to create value**
- ✓ **Have sufficient cash to finance R&D**
- ✓ **Gain access to non-dilutive funding**
- ✓ **Reduce the failure potential and maximize the success potential**
  - Commercialization by established partners
  - Select and prioritize assets through the scientific and commercial lens
  - Accept the development risk for the commercial gain


basilea

Marc Engelhardt

Chief Medical Officer

Successful products




basilea
Future

Portfolio USPs

- Serious infections (in hospital)
- Medical need
- Innovative and differentiated for successful commercialization

basilea

Our portfolio

basilea

1 The registration status and approved indications may vary from country to country.
2 Formerly GR-2397
3 Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).
4 Exclusive option to in-license upon completion of preclinical profiling
5 CARB-X's funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany's Federal Ministry of Education and Research (BMBF).

High medical need in invasive fungal infections

The new assets in our drug pipeline

basilea

1 The registration status and approved indications may vary from country to country.
2 Formerly GR-2397
3 Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).
4 Exclusive option to in-license upon completion of preclinical profiling
5 CARB-X's funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany's Federal Ministry of Education and Research (BMBF).


basilea
Fosmanogepix
An attractive asset with high potential



Fosmanogepix: an attractive asset with high potential



Fosmanogepix

Innovative, new class of antifungal

- Broad spectrum antifungal activity against yeasts, molds and dimorphic fungi
- May become the treatment of choice for a wide range of difficult to treat fungal infections
- Planned global phase 3 program includes two studies in yeast and in mold infections


basilea
Fosmanogepix saving lives
in fungal meningitis outbreaks

basilea

1 The registration status and approved indications may vary from country to country.
2 Formerly GR-2397
3 Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).
4 Exclusive option to in-license upon completion of preclinical profiling
5 CARB-X's funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany's Federal Ministry of Education and Research (BMBF).

basilea

BAL2062

The fastest acting drug in Aspergillosis

basilea

BAL2062



BAL2062

First-in-class, fast-acting antifungal

- First-in-class antifungal with novel mechanism of action for intravenous administration
- Rapid fungicidal activity in vitro against Aspergillus spp.
- Lack of cross resistance with marketed antifungal agents
- Low propensity for drug-drug interactions
- Potential to be superior to other antifungals in the treatment of invasive aspergillosis
- Preclinical profiling to inform clinical development program aimed for demonstrating superiority

High medical need in bacterial infections

basilea

1 The registration status and approved indications may vary from country to country.
2 Formerly GR-2397
3 Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).
4 Exclusive option to in-license upon completion of preclinical profiling
5 CARB-X's funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany's Federal Ministry of Education and Research (BMBF).

basilea

Tonabacase

Great potential of showing superiority

basilea

Tonabacase (endolysin) effects on Gram-positive bacteria





Tonabacase

Innovative new class of antibiotic

- Innovative new class of antibiotic (endolysin), rapidly bactericidal
- Effective against biofilms
- Low risk of resistance development
- Different from exebacase, due to ability of multiple dosing
- Preclinical profiling to inform clinical development program aimed for demonstrating superiority
- Clinical development in serious staphylococcal infections such as endocarditis as add-on to standard of care antibiotics

basilea

1 The registration status and approved indications may vary from country to country.
2 Formerly GR-2397
3 Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).
4 Exclusive option to in-license upon completion of preclinical profiling
5 CARB-X's funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany's Federal Ministry of Education and Research (BMBF).


basilea
LptA inhibitor

LptA inhibitor

Late preclinical antibacterial compound(s)

- Innovative mode of action
- Targeted spectrum against most frequent Gram-negative bacteria
- Expected to overcome resistance in serious Gram-negative infections
- Non-dilutive funding by CARB-X
- Initiation of clinical development expected in 2026

basilea

Overview:
new drugs in our pipeline

Antifungals

- Fosmanogepix
- BAL2062

Antibacterials

- Tonabacase
- LptA inhibitor

Our recipe for success

How we create anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
  - Focus on areas with meaningful market opportunity today
  - Focus on high priority diseases/pathogens
- ✓ **Extend portfolio with external assets**
  - Affordable assets to in-license and acquire
- ✓ **Define right development stage to create value**
- ✓ **Have sufficient cash to finance R&D**
- ✓ **Gain access to non-dilutive funding**
- ✓ **Reduce the failure potential and maximize the success potential**
  - Commercialization by established partners
  - Select and prioritize assets through the scientific and commercial lens
  - Accept the development risk for the commercial gain


basilea

The future

2024 Priorities

basilea

Maximize Cresemba revenues

basilea

Zevtera US launch


basilea
Fosmanogepix
Start of phase 3 studies

basilea

BAL2062 & tonabacase

2025: Start of phase 2 studies


basilea
Products / Product candidates / Indication
Preclinical
Phase 1
Phase 2
Phase 3
Market
Antifungals
Cresemba® (isavuconaz
Invasive aspergillosis and mucormyco
Aspergillosis (including invasive asp
cryptococcosis (Japan)
Fosmanogepix
Candidemia / invasive candidiasis (including Candida aur
invasive mold infections including invasive aspergillosis,
mucormycosis and other rare mold infections)
BAL2062[2]
Invasive aspergillosis
Antibiotics
Zevtera® (ceftobiprole)
Hospital- and community-acquired bacterial pne
countries)
Staphylococcus aureus bacteremia (SAB)[3], acu
community-acquired bacterial pneumonia (C
Tonabacase[4]
Severe staphylococcal infections
LptA inhibitor[5]
Severe Enterobacteriaceae infections
Internal research
Focus for in-licensing and acquisitions
Broaden our portfolio

Solid financial basis


basilea
Thank you!

Disclaimer and forward-looking statements

This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers”, and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea’s products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law.